TherapeuticsMD Elects Jules A. Musing to Board of Directors
News May 17, 2013
Mr. Musing has more than 36-years’ experience in the pharmaceutical and biotechnology industry and has been President and Managing Director of Johnson & Johnson subsidiary companies in the United States and Europe; President of Ares Serono, Inc. in the United States; and Executive Vice President of Ares Serono in North and Latin America.
In the course of his career at Johnson & Johnson, Mr. Musing was responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies, as well as the establishment of strategic alliances. This included the establishment of new scientific, technology and product collaborations in various therapeutic areas; the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide; and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets. In this position he negotiated and signed several multi-million dollar deals with small, medium and large pharmaceutical and biotechnology companies on a global basis.
He also has been on the Board of Directors of Johnson & Johnson companies in Germany, France, Italy and the UK and has been a member of the Management Board of Ortho Biotech (a Johnson & Johnson biotechnology company) in the United States and Europe.
Early on in his career, Mr. Musing was responsible for the business development activities of Janssen Pharmaceutica in S.E. Asia, where he was instrumental in the establishment of Johnson & Johnson pharmaceutical subsidiaries in Japan, Australia, South Africa, Thailand, and other S.E. Asian countries. He also was Vice President, Marketing International for the Janssen Group of Companies Worldwide.
“We are pleased to welcome Mr. Musing to the Board,” said the Honorable Tommy G. Thompson, Chairman of the Board, TherapeuticsMD. “During Mr. Musing’s extensive and distinguished career at Johnson & Johnson, he established numerous strategic and global partnerships on many different fronts. The knowledge gained from those accomplishments is sure to offer valuable insight and direction to the company going forward.”
“Mr. Musing’s hands-on industry experience, in addition to having had direct responsibility for establishing various new product collaborations, will prove invaluable as we prepare to commence Phase III clinical trials on three of our hormone therapy development candidates,” said Robert G. Finizio, Chief Executive Officer.
“I am excited to join the TherapeuticsMD Board at this pivotal time in the company’s development,” said Mr. Musing. “I look forward to working closely with this experienced and dedicated senior management team.”
Mr. Musing presently serves on the Board of Directors of Delphi Digital, Inc. and is Chairman of the Scientific Advisory Board of Noble Capital Financial Markets. In addition, he has been a member of the Board of Directors of iBio, Inc.
Mr. Musing received his Master’s Degree in Biological Sciences from the University of Brussels, and his Graduate Degree in Economics and Financial Sciences from the University of Antwerp, in Belgium.